Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Other Financing Activities

Financing cash flows not reported separately.

Organogenesis Holdings Inc.NASDAQ: ORGO

Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026

Other financing activities grows, but more slowly than its trailing trend

Q1 FY2026 other financing activities of $10.37M (cash outflow) rose 477.6% year over year, behind the +1246.5% change in trailing-twelve-month other financing activities. Sequentially, it rose 130.1% from the prior quarter.

Context

  • Other financing activities amounted to 2.9% of revenue in FY2025, up 2.5 pp from a year earlier.
  • Other financing activities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +477.6% toward the trailing-twelve-month pace of +1246.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$10.37M+130.1% QoQ
Last fiscal yearDec 2025
-$16.35M-974.1% YoY
LTMMar 2026
-$24.92M+1246.5% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+477.6%——
1 year-974.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
(16.35M) USD
Year-over-year change
-974.1%

Other Financing Activities vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1246.5% is the highest of 10, against a peer median of +105.9%.
  • Other financing activities amounts to 4.9% of revenue for ORGO, versus a peer median of 0.4%.
ORGO Competitors
Other Financing Activities for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$24.92M USD+1246.5%—4.9%
EOLSEvolus, Inc.LTM Mar 2026$16.2M USD+496.5%—5.4%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$9.34M USD+926.3%+28.9%—
VREXVarex Imaging CorporationLTM Apr 2026$8.8M USD+1000.0%—1.0%
EBSEmergent BioSolutions Inc.LTM Mar 2026$3.7M USD-208.8%+15.9%0.5%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$1.2M USD+477.4%+145.6%—
SNDLSNDL Inc.LTM Mar 2026CA$834K CAD-10.0%-77.5%0.1%
SIGASIGA Technologies, Inc.LTM Mar 2026$581K USD—+225.9%0.6%
ANGOAngioDynamics, Inc.LTM Feb 2026$295K USD+105.9%—0.1%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$244K USD+103.3%—0.1%
BCYCBicycle Therapeutics plcLTM Mar 2026$130.84K USD-256.2%—0.2%
Peer median (excluding ORGO) —+105.9%+28.9%0.4%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income94.9M15.53M4.95M861K37.03M
Depreciation & Amortization16.68M10.73M23.45M17.03M26.94M
Deferred Income Tax(31.98M)1.98M2.01M(10.72M)9.5M
Stock-Based Compensation3.86M6.55M9M10.58M13.3M
Change in Working Capital(39.29M)(34.08M)(18.07M)(48.89M)(132.38M)
Accounts Receivables(30.23M)(8.77M)5.54M(31.8M)(115.8M)
Inventory(9.3M)(9.41M)6.58M(6.2M)(17.92M)
Accounts Payables3.85M3.26M(108K)(2.37M)(528K)
Other Working Capital(3.6M)(19.16M)(30.08M)(8.51M)1.87M
Other Non-Cash Items17.8M24.15M9.59M45.35M35.3M
Operating Cash Flow61.98M24.86M30.92M14.21M(10.31M)
Capital Expenditures(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(31.22M)(33.9M)(24.36M)(10.03M)(14.15M)
Debt Repayment(2.01M)(3.01M)(5.17M)(67.64M)(1.17M)
Common Stock Issued2.2M000157K
Common Stock Repurchased000(25.48M)0
Dividends Paid000(1.8M)0
Other Financing Activities(1.22M)814K(332K)1.87M(16.35M)
Financing Cash Flow(1.04M)(2.2M)(5.51M)27.64M(17.36M)
Effect of Forex Changes00000
Net Change in Cash29.72M(11.24M)1.05M31.81M(41.82M)
Free Cash Flow30.76M(9.04M)6.55M4.18M(24.46M)

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.